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ABSTRACT  
This is a prospective hospital based and case control study done in 
Soba University Hospital and Khartoum Teaching Hospital during the 
period from August 2004 to March 2005.  
The objectives of the study were to assess (a) the impact of  
pregnancy induced hypertention (PIH) on neonatal growth parameters, 
(b) perinatal causes of morbidity and  mortality in infants born to mothers 
with PIH and (c) knowledge, attitude and practice of mothers with PIH 
toward the effect of PIH on  her neonate and neonatal care. 
 The study included 140 singleton newborns of mothers having 
PIH matched with 140 singleton newborns of  normotensive mothers.The 
research tools included questionnaire, physical examination, gestation age 
assessment, anthropometry and follow up of newborns for six days. 
 PIH was found to significantly lower head circumference, length, 
weight and chest circumference of newborns compared to controls             
(P< 0.0001). The severity of PIH ( pre-eclampsia, sever pre-eclampsia 
and eclampsia) proportionately lowered the length and weight of 
newborns  to a significant effect( P<0.006 & P<0.012) respectively but 
did not have significant effect on head circumference of newborns cases 
compared to controls (P=0.077). About quarter of newborns cases were 
preterm. The risk of hypoglycaemia was two times higher in infants of 
mothers with PIH than controls (RR=2.1;95%CI 1.85-2.38). Newborns of 
 iii
mothers with PIH were at greater risk of having perinatal asphyxia and 
hypothermia than newborns of controls.OR 5.52(95%CI 1.19-2.57) and 
OR 6.75(95% CI 2.5-18.I) respevtively.There were no significant 
difference in outcome of stillbirth in cases or controls( P=0.060), (RR 
0.49; 95% CI 0.44-0.55). Mothers with PIH were knowlegeable about 
impact of PIH on newborns than control mothers but there were no 
significant differences between them regarding neonatal care.Its 
concluded that newborns to mothers with PIH have lower growth 
parameters and are more prone to perinatal complications compared to 
controls.  
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1-INTRODUCTION AND LITERATURE 
REVIEW 
 
1-1 Definition: 
       Pregnancy induced hypertension (PIH) is occurrence of blood 
pressure of 140/90 mmHg or more on at least two occasions four 
hours or more apart, after the 20th week of pregnancy in a woman 
known to be normotensive before this time and in whom blood 
pressure (BP) has returned to normal by the sixth postpartum week. 
This definition of PIH, however, does not distinguish borderline 
essential hypertension from true PIH. Therefore an increment of at 
least 25 mmHg in diastolic pressure should perhaps be allowed for 
during pregnancy.(1) 
PIH occurs in about 7-10 % of all pregnancies, it complicates 
16-24 % of the first pregnancies and 12-15 % of subsequent 
pregnancies. (2, 3) 
 
1-2 Predisposing factors :( Risk factors): 
     The cause of PIH is unknown. Some conditions may increase 
the risk of developing PIH, including the following. 
Pregnant for the first time.  
Family history of PIH. 
Mothers age younger than 15 or older than 40. 
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History of chronic hypertension or PIH. 
Multiple births (twins, triplets, etc) 
Medical conditions such as diabetes or kidney diseases.(2,4,5) 
Obesity. 
Thyroid disease. 
Sickle cell anemia. 
Collagen vascular disease. 
Molar gestations.(6) 
 
1-3 Etiology of PIH:- 
       IN 1916 pre-eclampsia was called the disease of theories; 
almost a century later, this characterization is still accurate. 
Despite extensive interest research, the cause of pre-eclampsia 
remains uncertain. There are however, well recognized 
predisposing factors as well as data to support contributions from 
several areas in the pathogenesis.(7) 
 
1-3-1 Immunogenetic factors: 
Because pre-eclampsia most often occurs in first pregnancies, 
it is tempting to speculate that an aberrant immune reaction to 
foreign paternally derived antigens (sperm) is responsible for the 
disease. Following this line of reasoning, the lower rates of pre-
eclampsia in second pregnancies might imply a protective effect 
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incurred by prior exposure to either paternal or unknown placental 
antigen. Exposure to fetal antigen parse is not required to develop 
pre-eclampsia because the disease is well recognized complication 
of hydatiform mole. Two observations indirectly support an 
immunogenetic hypothesis. First, the rate of pre-eclampsia is 
increased in pregnancies conceived by a new reproductive partner 
or using donor insemination. Second, the rate of pre-eclampsia is 
increased in women becoming pregnant after using a birth control 
method that prevents semen exposure and is comparatively 
decreased by longer periods of cohabitation prior to pregnancy. .(8) 
      A familial predisposition to pre-eclampsia is well 
established and may operate primarily as a single gene recessive 
trait. Because women with pre-eclampsia are more likely to be 
positive for HLA-DR4 than normal women, it has been suggested 
that a defect could lie in a recessive immune response gene linked 
to HLA. However, one group found no association between HLA-
A and - B and pre-eclampsia. 
     Assuming autosomal recessive inheritance, investigators 
failed to find linkage using random DNA markers in families with 
pre-eclampsia. In contrast, another group found that a molecular 
variant of the angiotensinogen gene, known to be associated with 
essential hypertension, also is associated with primigravida pre-
eclampsia. Women have a genetic predisposition to develop pre-
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eclampsia, (9) although the wide variation in presentation of the 
condition means that the mode of inheritance is uncertain. 
Exclusion mapping found no evidence for linkage to the HLA 
region and indicated that the pre-eclampsia gene was most likely to 
lay on chromosome 1, 3, 9, or 18 (10). In 1993 Wardetal described a 
mutation in the angiotensinogen (chromosome 1), which seemed to 
be associated with an increased tendency to pre-eclampsia. Given 
the changes in the rennin-angiotensin system in pre-eclampsia this 
generated considerable interest. At present, however, the observed 
effect seems to be specific to certain populations.(11) 
An autoimmune connection to pre-eclampsia also is suspected. 
Some, but not all, investigators have found reduced circulating 
levels of complement factors (C3 and C4) in pre-eclampsia 
patients. Antiphospholipid syndrome, an autoimmune condition, is 
associated with particularly high rates of pre-eclampsia in women 
progressing beyond 15-20 weeks of gestation. Furthermore, 
approximately 15% of women with severe pre-eclampsia of onset 
before 34 weeks of gestation have significant levels of 
antiphosphlipid antibodies. .(7) 
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1-3-2 Increased vascular reactivity and endothelial injury: 
The underlying abnormality in pre-eclampsia involves 
increased vascular sensitivity to presser hormones and eicosanoids 
and general arterial constriction. In turn, increased vasoconstriction 
results in increased blood flow resistance and arterial 
hypertension.(7) 
 
1-3-3 Lipid peroxidation: 
The role of lipid per-oxidation in PIH is increasingly being 
investigated. Free oxygen radicals in the body cause various types 
of damages, including lipid per oxidation and subsequent 
endothelial cell injury and damage to proteins and nucleic acids in 
pregnancies with established pre-eclampsia is increased.(12) One 
recent cross sectional study found a strong correlation between 
concentrations of the products of lipid per oxidation and the mean 
arterial pressure. 
Cells and tissues are usually protected from the effects of 
lipid per oxidation by several naturally occurring antioxidants. A 
serum measurement of antioxidant activity which is normal rise 
during pregnancy is diminished in women with pre-eclampsia.(13) 
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1-3-4 Endothelial dysfunction: 
Generalized endothelial dysfunction in pre-eclampsia has 
been reviewed. It could certainly account for such phenomena as 
platelet activation and the increased circulating concentrations of 
fibronectin and factor VIII antigens. Disruption of endothelial 
integrity would also be associated with general loss of vasodilator 
capacity, which could account for enhanced presser response to 
angiotensins II and noradrenalin, were first described more than 25 
years ago in pre-eclamptic women and repeatedly confirmed. 
Another endothelial derived vasodilator is nitric oxide, which is 
endothelial derived relaxation factor. Super oxide easily breaks 
down nitric oxide, so the balance between oxygen and nitric oxide 
is likely to be one of the control mechanisms of vascular tone. (14,15)        
Widespread disturbance of the maternal vascular 
endothelium is responsible for the hypertension, altered vascular 
activity, activation of the coagulation cascade and the multi system 
damage which accompany PIH. Serum markers of endothelial cell 
activation or dysfunction (e.g.: Von Willebrand factors, fibronectin) 
are increased and may precede the onset of clinical disease by 
weeks or months. 
The endothelium is important in the modulation of vascular 
tone. Disturbance of endothelial cells, in pre-eclampsia leads to 
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alterations in the production of several vasoactive compounds 
producing a vasoconstrictor state.  
- Plasma prostacyclin (PGI2), the predominant vasodilator 
prostanoid, is reduced while placental production of the 
vasoconstrictor Thromboxane A2 is increased.  
- Plasma endothelin1, a potent vasoconstrictor, is increased. (16)        
 
1-3-5 Membrane Fluidity:  
Changes in the cells membrane that affect the 
functioning of receptors may also be important in PIH and pre-
eclampsia. In studies using platelets as models of vascular smooth 
muscle, the density of binding sites for angiotensin II was lower in 
women during a normal pregnancy than in those how were not 
pregnant but was unchanged in women with established disease (17). 
A prospective study done in primigravidas, those how remained 
normotensive showed there were a very rapid fall in binding sites 
for angiotensinП during the first few weeks of pregnancy, such a 
fall in binding sites for angiotensin П not occur in nulliparous 
women who develop PIH. (18) Membrane fluidity is altered in 
established PIH and pre-eclampsia. Plasma concentrations of 
polyunsaturated fatty acids are lower in established disease than in 
normal pregnancy, which might contribute to the change. (19). 
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1-3-6 Calcium: 
Lipid peroxidation in cell membranes increases their 
permeability to calcium. Prospective studies have shown a slow 
rise in platelet intracellular free calcium concentration with 
gestation in normotensive primigravidas, the concentration being 
significantly raised by the third trimester in women with pre-
eclampsia. This may contribute to the efficacy of calcium channel 
blockers in treatment of PIH. (20)    
 
1-4 Pathology: 
The placenta is central to the pathogenesis of pre-
eclampsia. The incidence correlates with placental mass being 
higher in twin’s pregnancy, molar pregnancy and hydropsfetalis. In 
contrast to normal pregnancy, endovascular trophoblast invasion 
remains superficial, rarely if ever reaching the myometrial 
segments this appears to be associated with a failure of integrin 
switching. As a result the spiral arteries remain muscular, undilated 
and respond to vasomotor influences. Uteroplacental blood flow is 
therefore reduced. Many vessels also show acute  atherosclerosis in 
which there is fatty change in intimal cells, necrosis of the vessel 
wall and luminal occlusion by aggregates of fibrin, platelets and 
lipid-laden macrophages. Failure of trophoblast invasion is not 
pathgnomonic of pre-eclampsia since similar abnormalities have 
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been reported in some women with PIH, chronic hypertension and 
women with fetal growth retardation without maternal 
hypertension. 
In women with PIH placental biopsy specimens show 
clearly that the development of the placenta has been impaired 
from start. The trophoblast fails fully to invade and thus the spiral 
arteries dilate to only 40% of that in normal pregnancy, which 
impairs the massive increase in uteroplacental perfusion in the 
second half of pregnancy. The failure of dilatation will thus cause, 
in latter pregnancy, placental hypoxia, which may itself result in 
the systemic manifestation of the disease.(16)   
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1-5 Classifications:  
1-5-1 Gestational hypertension:  
Is increase in blood pressure without proteinuria.  
1-5-2  Pre-eclampsia: 
Is a condition when proteinuria of 500mg/L or more in 
addition to high blood pressure. It complicates 3-5% of first 
pregnancies, 1% of subsequent pregnancies and 5-10% of cases 
being severe (1). 
1-5-3 Severe pre-eclampsia: 
- Blood pressure ≥ 160mmHg systolic or ≥ 110mmHg 
diastolic on at least two occasions four hours apart with 
patient at rest. 
- Proteinuria is more than 5g/24 hours. 
- Oliguria less than 400mL in 24 hours. 
- Cerebral or visual disturbance. 
- Epigastric pain. 
- Pulmonary edema or cyanosis. 
- Impaired liver function. 
- Thrombocytopenia.(3) 
- Headache. 
- Nausea and Vomiting. 
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1-5-4 Eclampsia: 
Is a severe form of PIH in which women have seizures in 
association with features of pre-eclampsia. It occurs in about one 
in 1600 pregnancies and it develops near the end of pregnancies in 
most cases.(3)It occurs unexpectedly in about one in 2000. In the 
United Kingdom more than one third of cases occur before the 
classic warning signs of both proteinuria and hypertension. 44%of 
cases occur postpartum. (1) 
 
1-5-5  Hellp syndrome:    
      Is a complication of severe pre-eclampsia or eclampsia. It 
is a group of physical changes, including the break down of blood 
cells, change in liver function and low platelets. (2) 
     Clinical experience suggests that many women who 
develop PIH in the second trimester will show steadily worsening 
hypertension, accompanied by development proteinuria, 
thrombocytopenia, and end failing renal and hepatic function. If 
the disease start later or delivery is expedited, however, pre-
eclampsia may never occur. (21) 
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1-6 Diagnosis: 
Pre-eclampsia is a syndrome (a group of symptoms or 
signs) which can be recognized but not diagnosed because there is 
no specific diagnostic test. The presentation is very variable and 
although hypertension and proteinuria are the two signs most 
easily detected, they are not central to the pathogenesis of the 
disorder. No single feature is consistently present. 20% of women 
with eclampsia are normotensive and 30% have no premonitory 
proteinuria.Early recognition of the syndrome requires screening 
for organ  involvement (3) 
Is there a family history of PIH or pre-eclampsia? Will 
immediately identify a group of women at higher risk when the 
answer is yes, such women will merit extra care.  
Reliable reading of maternal of blood pressure are 
needed from early pregnancy, certainly before 20 weeks gestation. 
It will provide a base line from which to assess the rise in pressure 
as pregnancy progresses for each woman. 
The women weight and height should be measured at 
least at the first visit. (22) An early base line platelet count will aid 
later interpretation. A fall in platelet count is characteristic of the 
disease in its later stage. (1) Urine testing. Assessment of edema. 
Frequent weight measurement. Eye examination to check for 
retinal changes. Liver and kidney function tests. (2) 
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1-7  Management: 
1-7-1 Conservative management:  
           Admission to hospital (as specialized personnel and 
equipment may be necessary). The goal of treatment is to prevent 
the condition from becoming worse and to prevent it from causing 
other complication. Pregnancy beyond 34 weeks of gestation 
should be delivered. Perform amniocentesis for fetal lung maturity 
if the patient is 32-34 weeks of gestation. If the fetus is mature then 
the patient is delivered. Alternatively, if pulmonary maturity is not 
demonstrated, glucocorticoids are administered and the fetus is 
delivered 48 hours later. Patient who is between 24-32 weeks of 
gestation may be candidates for conservative treatment. 
Pregnancies less than 24 weeks carry a poor prognosis. 
Sibai et al observed 75% rate of neonatal survival for patient 
conservatively as compared with 35% survival when patients were 
delivered immediately. (23)       
 
1-7-2  Drugs treatment:  
The use of anti hypertensive agents to control BP 
should be considered if levels are consistently above 
160/100mmHg. They may help to prolong the pregnancy for a 
clinically useful period in term of neonatal out come.   
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 Methyldopa has a long safety history in pregnancy and is 
often used for chronic control of BP in pregnant women. 
 B-blockers are associated with fetal growth retardation when 
used from early in pregnancy, but this does not appear to be a 
problem when they are prescribed in the third trimester. 
 Calcium channel blockers such as nifidipine which can be 
useful for the rapid control of severe hypertension in the sublingual 
form, as well as a second line agent for longer term control in slow 
release preparations.  
 Angiotensin converting enzymes inhibitors should not be 
used in pregnancy as they have associated with fetal renal failure, 
oligohydramnous and still birth. (24,25) 
 Hydralazine or labetalol are useful for the acute control of 
severe hypertension prior to delivery.  
The aim of using drugs treatment is to reduce maternal BP 
gradually to safer levels e.g. 135/85 mmHg in a usually 
normotensive women. Hypotension is avoided as uteroplacental 
blood flow may be adversely affected and possibly precipitate fetal 
distress. 
In using anticonvulsant drugs in eclamptic patients, the 
neonatal outcome is better in the women who were prescribed 
magnesium sulphate rather than phenytoin. A systemic overview 
of several randomized trials suggests that magnesium sulphate is 
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also a better than phenytoin and diazepam at preventing 
convulsions. Magnesium administered pareterally to the mother 
promptly crosses the placenta to achieve equilibrium in fetal serum. 
The neonate may be depressed only if there is severe 
hypermagnesemia at delivery. No observed neonatal comparisons 
after therapy with magnesium. (24)  
1-8  Prevention: 
 Early identification of women at risk for PIH may help prevent 
some complications of the disease. 
Education about the warning symptoms is important because 
early recognition may help women to receive treatment and 
prevent worsening of the disease.(2) 
Aspirin inhibits the synthesis of prostaglandins by inactivating 
cyclo-oxygenase. Low dose therapy is being studied as one 
possible way to prevent the chemical imbalance at the placenta, 
which believed to be a cause of pre-eclampsia.  
Fish oil, marine n-3 fatty acids are known to reduce the 
formation of thromboxane A2 with little or no affect on 
prostocyclin. Population with a very high intake of fish oils also 
appears to have a low incidence of pre-eclampsia. Data from 
several randomized trials have failed to demonstrate any reduction 
in the incidence of pre-eclampsia.( 26,27) 
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 Low sodium diet has been prescribed. However randomized 
clinical trials in nulliparous women, sodium restriction to ≤ 
50mmol had no affect on maternal blood pressure or obstetric 
outcomes (birth weight, gestational age or mortality). (28) 
Belizan et al. Reported that women receiving elemental calcium 
after 20th weeks of gestation has significantly less hypertensive 
disease than the control group (9.8 vs. 14.8%, respectively ). (29) 
Until the etiology of pre-eclampsia is better understood, it is 
unlikely that an effected prophylactic agent will emerge. (30)        
        
1.9 Normal growth and development of the infant: 
Growth and development at and  after 20th week of gestation 
at time PIH can develop. 
20 weeks; usual lower limit of viability at which weight 460g and 
length 19cm.At 25 weeks weight 900g and length 25 cm. At 28 
weeks weight 1300g. 
During the 3rd trimester, weight triples and length doubles as 
body stores protein, fat, iron and calcium. (31) 
The fetal weight increases linearly until the 37th week at a 
rate of approximately 15g per day. At term fetal weight, 
approximately 3400g at birth male weight exceeds female weight 
by approximately 100g. (32) 
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1-10 intrauterine growth retardation: 
1-10-1 Definition: 
Intrauterine growth retardation (IUGR) has been variously 
defined as a birth weight of less than 2500g at term or a weight or 
length that is less than the 10th percentile or below two standard 
deviation (2SD) for gestational age (33) 
 In toxemia of pregnancy, there is increase platelet 
aggregation & abnormalities in uteroplacental circulation. Low 
dose of aspirin (150mg per day) administered to women at risk for 
fetal growth retardation resulted in a 225g newborn weight 
increase over the placebo group .The beneficial effect of low dose 
aspirin related to inhibition of the synthesis of thromboxane B2, 
which decrease the platelet aggregation and placental vasocclusion 
seen in toxemic state. 
 
1.11 Complications of the Infant with IUGR: 
The quality of life in growth-retarded infants is compromised. 
They are predisposed to a variety of complications. These 
complications are secondary to intrauterine malnutrition. 
Appropriate management can prevent many of these complications. 
(33) 
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1-11-1 Meconium Aspiration Syndromes: 
Since placental insufficiency is a common cause of growth 
retardation, these babies frequently suffer from fetal hypoxia. 
When subjected to hypoxia the fetus may expel meconium in to the 
amniotic cavity. The infant may aspirate this meconium, either in 
utero or immediately after birth resulting in the meconium 
aspiration syndrome. But it is rare in infants less than 35weeks 
gestation; therefore hypoxia per se is the major problem in those 
infants. (33) 
1-11-2 Hypoglycemia: 
   Frequently found in the immediate postnatal period.   
1.11.3 Hypothermia: 
         Common in growth-retarded infants. They have less 
subcutaneous fat provides poor insulation and diminished ability to 
conserve heat.. (34) 
1.11.4 Birth asphyxia: 
           Is an important cause of a permanent damage to CNS cells, 
which may result in neonatal death or which may be manifest later 
as cerebral palsy or mental deficiency.    
1.11.5 Hyaline Membrane Disease: 
Is generally less of a problem in infants with disproportionate 
IUGR because of the accelerated lung maturation seen in these 
infants. 
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1.11.6 Persistent Fetal Circulation: 
Some asphyxiated newborns exhibit significant right to left 
cardiac shunting, making systemic oxygenation difficult to achieve.   
1.11.7 Polycythyemia: 
 Hyper viscosity and hypoglycaemia are primarily problem of 
nutritionally growth retarded newborn. Hyperviscosity secondary 
to polycythemia in infants with IUGR can result in venous 
thrombosis and central nervous system injury and can contribute to 
hypoglycaemia.  
1.11.8 Hypocalcaemia: 
Occur in the newborn with IUGR. Generally, in associated 
with neonatal stress. (33,35) 
 
 1-12 Preterm newborn: 
1-12-1 Definition: 
A preterm newborn is a living born infant delivered before 37 
weeks from the first day of the last menstrual period. (36)                                         
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1.13 Complications of Preterm newborn: 
1-13-1 Respiratory Distress Syndrome (Hyaline Membrane 
Disease): 
Is a major cause of illness and death in the preterm infants in 
developed countries.  It occurs in babies born earlier than 32 to 34 
weeks who may have inadequate surfactant. (37,38) 
1-13-2 Apnea: Is a respiratory pause of 20 seconds or longer, or 
a shorter pause associated with cyanosis, abrupt pallor or 
hypotonic or Bradycardia. (39)  
1-13-3 Necrotizing Enterocolitis:              
 Necrotizing enterocolitis may be related to ischemic insult that 
damages the bowel lining & homers mucus productions, rendering 
the bowel susceptible to infection.  
1-13-4 Physiological jaundice:                                                         
Physiological jaundice is the result of increased bilirubin 
production at a time when the mechanisms for liver up take, 
transport and conjugation are immature.  
Preterm infants exhibit a higher serum bilirubin level, occurring 
on days five. (40) 
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1-13-5 Hypoglycaemia:                
Definition: 
Is blood glucose level less than 1.7mmol/L in period less than 
48 hours.  Or less than 2.2mmol/l in more than 48 hours in term 
infant 
In preterm infant hypoglycaemia is defined as blood glucose 
less than 1.1mmol/L at any time. (41) 
1-13-6 Hypocalcaemia: 
Defined as total serum calcium below 1.75mmol/L or, 
ionized calcium below 0.625mmol/L. 
1-13-7 Infections:      
1. In developing countries, preterm infants have a prevalence 
of sepsis estimated at 30% to 60&, with morality rate of 40 to 70. 
1-13-8 Hypothermia:     
Is a body temperature below 36C rectal.  
1-13-9 Intra ventricular Hemorrhage (IVH):                                 
The incidence of GMH/IVH increases as gestational age 
decreases and as many as 50% of infants of less than 25 to 26 
weeks gestation have the disorder.  
1-13-10 Hypotension:     
Hypotension is a common problem in sick infants with very 
low birth weight. (42)  
 
 22
1-14   Studies done in Sudan:  
    That study by Hamed Murad in Essuki hospital from October 
1979 – October 1980, there were 1446 obstetric cases admitted to 
the ward. There were seven cases presented with eclamptic fits 
(incidence 0.48%), three of them stillborn and one died on the 
second day giving a perinatal mortality of    57 %( 43). 
Omer Ahmed study 923 obstetric cases admitted to the ward in 
Dongolla hospital from September 1977 to February 1981. There 
were 16 cases presented with eclampsia, incidence of 1.7%. The 
perinatal mortality was 60 %( 44). 
In a study done in Omdurman maternity hospital during 1995. 
82 patients with eclampsia were studied. The perinatal mortality 
was 14.2%. Prematurity was the commonest cause of perinatal 
death (45). 
An other Study was carried out by Dr Khalid in Omdurman 
hospital from 26th March to 10th May 1994.It showed that pre-
eclampsia was a significant cause of LBW. Mothers with pre-
eclampsia have a chance of two times to have LBW in comparison 
to normotensive (46). 
Study done by Dr Salwa in Omdurman maternity hospital. She 
found that PIH significantly cause low birth weight (P value 
<0.001). (47) 
   
 23
1-15 Studies worldwide: 
Study of all births of the province Scotia, Canada, between 
1988 – 2000, showed that women with gestational hypertension 
without proteinuria and with proteinuria were more likely to have 
infants with SGA (RR 1.5, 95% CI, 1.4 – 1.6 and RR 3.2, 95% CI 
2.8 – 3.6 respectively)(48).      
A cohort study done in U.S.A to examined the effect of pre-
eclampsia on fetal growth, showed that after adjusting for maternal 
age, race, smoking, medical status and gestational age, the OR for 
VLBW was 30.7 (95% CI 7.0 – 13.49). Pre-eclampsia was 
associated with a 3.8 fold increased risk of LBW (95% CI 1.9 – 
7.5). Women with pre-eclampsia were 3.6 times more likely to 
deliver SGA newborns as compared with normotensive women 
(95% CI 2.3 – 5.7) (49). 
A study done in Northern and Central Alberta, Canada 
showed that the differences in mean birth weight between women 
with pre-eclampsia and normotensive women ranged from 239.5g 
to 547.5g for gestational age categories ranging from < or = 32 
weeks to > or = 2 weeks. The birth weights were statistically 
significantly lower among mothers with pre-eclampsia who 
delivered at < or = 37 weeks, however, the birth weights were not 
lower among pre-eclamptic mothers who delivered after 37 
weeks(50). 
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Pre-eclampsia was associated with a 5% (95% confidence 
interval 3%, 6%) reduction in birth weight. In severe pre-eclampsia, 
the reduction was 12% (9%, 15%), and in early – onset disease, 
birth weight was 23% (18%, 29%) lower than expected. The risk 
of SGA was four times higher (RR = 4.2, 95% CI 2.2, 8.0) in 
infants born after pre-eclampsia than in control pregnancies. 
Among nulliparas, pre-eclampsia was associated with a nearly 
three fold higher risk of SGA (RR = 2.8; 95% CI 1.2 - 5. 9), and 
among multiparas, the risk of SGA was particularly higher after 
recurrent pre-eclampsia (RR= 12.3; 95 % CI 3. 9 – 39. 2) (51). 
Another study showed that women with pre-eclampsia were 
more likely than control patients to deliver a SGA infant (adjusted 
odds ratio 7.0, 95% CI 2.8 to 18.1). Multiparous women with pre-
eclampsia were at greater risk of having a SGA infant (adjusted 
odds ratio 29.4, 95% CI 5.2 to 167.5) than were nulliparous 
women (adjusted odds ratio 4.1, 95% CI 1.2 to 14.1) when 
compared with normotensive control patients of similar parity (52). 
A study showed that the majority of SGA infants occurred in 
the group with proteinuric pre-eclampsia (52%), where as the rate 
of SGA infant was 18% in the non proteinuric gestational 
hypertension (53). 
          Women who had recurrent pre-eclampsia experienced more 
preterm deliveries before 37 and 35 weeks of gestation than 
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nulliparous women who developed pre-eclampsia. In addition 
among women who developed severe pre-eclampsia, those with 
recurrent pre-eclampsia had higher rates of preterm delivery both 
before 37 weeks (67% vs. 33%, P= .0004) and before 33 weeks of 
gestation (36% vs. 19%, P= .041), and higher rates of fetal death 
than did nulliparous women (54).  
Another study showed that, women who developed severe 
gestational hypertension( without proteinuria) had higher rates of 
both preterm deliveries at <37 weeks of gestation and SGA infants. 
There were no statistically significant differences in perinatal 
outcomes between the normotensive, mild gestational hypertension 
and the mild pre-eclampsia groups (55). 
A retrospective analysis of 220 growth restricted fetuses in 
university – hospital at Homburg, showed that growth restricted 
fetuses born to hypertensive mothers had a significant lower birth 
weight (P < 0.05). The incidence of RDS in children born to 
hypertensive mothers was significantly higher (P < 0.05, P < 0.01) 
and they stayed significantly longer in the neonatal intensive care 
unit (P < 0.01). The perinatal mortality of infants born to 
hypertensive mothers was significantly higher (P < 0.05, P < 
0.01)(56). 
In a study done in Turkey, fetal loss was higher in women 
with recurrent pre-eclampsia (19.0%) than women with pre-
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eclampsia who had a normotensive pregnancy history (4.7%), with 
adjusted odds ratio (OR) of 5.77 [95% CI 0.84 – 39.54](57). 
There was a significant increase in the incidence of hyaline 
membrane disease in pre-eclamptic group overall (OR 1.35; 95% 
CI, 1.0 – 1.78). The risk was more pronounced in neonates who 
were born at 32 weeks of gestation (Odds ratio, 1.93; 95% CI, 1 – 
2.91) (58). 
In the Central Hospital in Maputo a total of 1275 consecutive 
cases of pregnancy associated hypertension was studied. The 
prevalence of LBW newborns were 20.1% in the live born groups, 
while it was 68.4% in the stillbirth.(59)                       
A case control study was carried out in 50 women with PIH and 80 
women with normal BP as a control group. There was found a 
higher incidence in premature birth (30 – 37th week of gestational 
age) and reduced weight in mothers with PIH than the control 
group. Evaluation of neonatal data at birth showed a lower apgar 
scores at 1st and 5th minutes of ages, a higher percentages of 
newborns transferred to neonatal intensive care unit and there were 
a higher percentage of still birth (14%) in the study group as 
opposed to the control group(60). 
The impact of hypertensive disorders in pregnancy on birth 
weight and neonatal outcomes were studied in 279 infants of 
hypertensive mothers and 279 controls at the Italian hospital of 
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Buenos Aires. The result showed that maternal hypertensive was 
significantly associated with a higher rate of caesarian section (OR : 
3.80; 95% CI : 2.64 – 5.50); SGA infants (OR : 7.08; 95% CL : 
3.07 – 18.6), LBW (OR : 1.8, 95% CI : 1.24 – 2.60) and VLBW 
infants (OR : 2.14; 95% CI : 1.13 – 4.19), and low apgar scores at 
5 minutes(OR 3.63; 95% CI 1.12-15.3),   necrotizing enterocolitis 
(OR 3.33; 95% CI 1.23 – 10.30) and polycythemia (OR :3.63; 95% 
CL : 1.12 – 15.3), necrotizing enterocolitis (OR 3.33; 95% CL 1.23 
– 10.30) and polycythemia (OR : 3.63; 95% CI : 1.12 – 15.3) was 
significantly increased in infants born to hypertensive mothers. 
There were no significant differences regarding other causes of 
neonatal morbidity and mortality (61). 
In China the effect of different types of PIH (gestational 
hypertension, pre-eclampsia, severe pre-eclampsia and eclampsia) 
on fetal growth were retrospectively studied: gestation was 0.6 
week shorter in women with severe pre-eclampsia than in 
normotensive women (P < .01). However, the risk of preterm birth 
was not increased with any classification of PIH. Pre-eclampsia 
and severe pre-eclampsia increased the risk of IUGR and LBW. 
However, the risk of LBW was not increased significantly for 
gestational hypertension (adjusted odds ratio 1.56 CI 1.00 – 2.4) (62). 
In Texas USA, a study showed that perinatal mortality was 
significantly higher in the normotensive than in the hypertension 
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group in preterm deliveries (30-3 versus 18.7%, OR 1.9 CI 1.3 – 
2.9. At term, hypertension pregnancies demonstrated significantly 
higher mortality than normotensive pregnancies (4.6% vs. 1.9%, 
OR 2.42 [95% CI 1.7 – 3.4]) (63).  
 A study was performed in the obstetric divisions of the 
University of Messina. 123 infants were born of women with PIH 
and 4670 were control infants. Between the two groups of infants 
there were significant differences with regard to incidence of 
prematurity, low apgar scores at birth and LBW. Five of the infants 
born to mothers with PIH were referred to the nursery (64).  
 A study done in Seoul, Korea, to determine the effect of mild 
versus severe maternal hypertension on the neonatal morbidity of 
39 infant with very low birth weight born to mothers with maternal 
hypertension. 
The result was that the mild and severe maternal hypertension 
groups had significantly lower birth weights and more infants SGA 
than did controls. The incidence of RDS, however, was significant 
lower in infants of mothers with mild hypertension than in those 
with mothers with severe hypertension. Those in the mild group 
had fewer days of ventilator therapy and lower O2 requirements 
than both the infants in the severe groups and controls infants. The 
incidence of apnea in the mild hypertension groups was 
significantly lower than that in the severe hypertension group (65). 
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 In Italy a study done to evaluate the rates of short-term 
neonatal complication: A group of 96 singleton pregnancies 
complicated by PIH and electively delivered before 36 weeks 
gestation. Apneoic crises, bradycardia and ventilator support were 
higher among cases than control (66). 
 A retrospective cohort study done in North Caronila, about 
hypertension disorders of pregnancy and stillbirth in 400000 
pregnant women. The result showed the risk of gestational 
hypertension and eclampsias were 36.6 & 6.0 per 1000 
pregnancies respectively. Pregnancies to patient with gestational 
hypertension were 1.42 (95% CI 1.15 – 1.79) times greater risk of 
terminating in late stillbirth, while the risk ratio for eclampsia 2.23 
(95% CI 1.51 -3.30) (67). 
 A study on effect of pre-eclampsia on neonatal morbidity 
showed significant smaller mean birth weight and longer nursing 
time in neonatal intensive care unit in the pre-eclampsia group. 
Also neonatal complications, longer time of ventilation and early 
neurological disorder are more frequent pre-eclamptic group than 
in control (68).  
 The association between PIH and early neonatal death was 
studies in Chapell Hill in 342 early neonatal deaths. Was found 
that moderate to severe PIH was associated with increased risk of 
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early neonatal death with OR = 1.8 for moderate and >2.2 for 
severe (69).  
The effect of PIH on pregnancy outcome was studied in 
Chicago USA, it was found that PIH was associated with a 
significant higher risk for adverse pregnancy outcome for fetal 
death (OR 1.9), prematurity (OR 1.6) and IUGR (OR 2.8). PIH 
associated with 168g reduction birth weight (70). 
A retrospective analysis was done to determine the incidence 
of      periventricular (PV) and intra ventricular hemorrhage (IVH) 
in singleton preterm infants weighing less than 1500g born to 
mothers with PIH to whom magnesium sulphate was administered. 
There were 254 singleton infants born to mothers with PIH and 
1083 born to mothers without PIH were studies. The incidence of 
severe PV - IVH was lower in infants born to mothers with PIH 
than in those without PIH (8.2% vs. 14.5% OR 0.43(95% CI 
0.61)(71). 
        Determination the incidence, clinical features, complications 
and perinatal outcomes in mothers having PIH studded by Buga G 
A. He found preterm (34%), LBW (19.9%), IUFD (11.2%), IUGR 
(6.6%) and neonatal death (3.8%). (72) 
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JUSTIFICATION 
 
 
 
• Pregnancy induced hypertension is common disease of 
pregnant women in Sudan and has adverse effect on the 
neonatal morbidity and mortality. 
• PIH is easy to diagnose at primary health care level and its 
impact in the newborns can be reduced. 
• More studies used to be done in Sudan to cover this area. 
 
 
 
 
 
 
 
 
 
 
 32
 
OBJECTIVES 
 
 
1. To assess the impact of PIH on Neonatal growth parameters 
(Head circumference, chest circumference, length and 
weight) and the effect on maturity. 
2. To evaluate perinatal causes of morbidity and mortality in 
children born to mothers with PIH. 
3. To assess knowledge, attitude and practice of mother with 
PIH toward the effect of PIH on her baby and neonatal care.    
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                    2- MATERIAL AND METHODS 
 
2.1. Study Design:  
Prospective hospital based case control study. 
2.2. Study Area: 
Labour suites and obstetric theaters at Soba University Hospital 
and Khartoum Teaching Hospital.  
2.3. Study Period: 
From august 2004 to march 2005. 
2.4. Study Population: 
2.4.1. Test Cases: 
All mothers and newborns of mothers with pregnancy 
induced hypertension born at Soba University Hospital and 
Khartoum Teaching Hospital on two-day weekly basis for 
each hospital. 
2.4.2. Control Cases: 
Control cases consisted of mothers and newborns of 
normotensive mothers. Matched by maternal age, gestational 
age and parity to the nearest date of birth. 
2.5. Inclusion criteria: 
• All singleton newborns of mothers with PIH and 
their mothers. 
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• All singleton newborns of normotensive mothers 
who satisfied control criteria with their mothers.  
2.6. Exclusion criteria: 
• Newborns with clinically detected major congenital 
malformation. 
• Newborns of mothers with PIH having other 
concomitant disease. 
• Newborns of mothers with essential hypertension or 
with no follow up card.  
• Multiple pregnancies.  
2.7. Sample Size: 
The sample size was calculated according to the equation: 
N = z2pg/d2     and was found to be 138 cases.   
N = Sample size, z = Statistical certainty (1.96 at 95% level of 
confidence) 
p = Prevalence (10%), q = Probability of failure (100% - 10% = 
90%) 
d = Desired margin of error (0.05 – 0.02) 
The controls group included 138 singleton newborns of 
normotensive mothers. Each case was matched for gestational age 
to one control newborn of normotensive mothers, with no other 
disease, matched for parity, age and gestational age to the nearest 
date of birth up to 48 hours. 
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2.8. Study Technique: 
2.8.1. Ethical consideration: 
- Consent was obtained from each hospital administration and 
each department of obstetric and gynecology. 
- Informed verbal consent was obtained from mothers. 
2.8.2. Research tools: 
2.8.2.1. Questionnaire:  
- Questionnaire which includes mother’s personal, medical, 
obstetric history and specific part for symptoms, signs of the 
disease, type of diagnosis and result of investigation. 
- Part of the questionnaire for the newborn on mode of 
delivery, Apgar scores, complications, management and 
outcomes. 
- Another part of the questionnaire for knowledge, attitude and 
practice of mothers towards the effect of PIH on the newborn 
care, breast feeding and weight gain.  
2.9. Physical examination: 
           An inelastic tape was used to determine the crown – heal 
length with the neonate lying flat, on a table with   neck rightening 
and legs extended. The head circumference (occipitofrontal) was 
measured with an inelastic tape whereas chest girth was 
determined at the nipple line.The birth weight was              
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measured without clothes using Seca scales balance (made by 
Sauglingswaage company in Germany). 
 Child growth charts were used to assess growth parameters of 
newborns.  
The gestational age of the infant was calculated by completed 
weeks of gestation from the first day of the last menstrual period 
and was also estimated using new Bollard score.  
Each baby was followed up daily for six days looking for any 
complications. Those who were discharged before six day of age 
were followed up by telephone, asking about complications. 
2.10. Research Team: 
- The researcher interviewed mothers, completed the 
questionnaire-attended deliveries, did anthropometry and 
followed up newborns. 
- Obstetric registrars on duty diagnosed cases of PIH. 
 
2. 11. Statistical Analysis:  
Data was entered into SPSS (Statistical package for social 
science) and chi squire test was used to 0.05 significant levels. 
Odds ratio, relative risk and confidence interval were calculated.  
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3- RESULTS 
 
The study included 140 newborns of mothers with PIH as 
cases and 140 newborns of mothers with normal blood pressure 
and no concomitant disease as a control group. 
They were matched for maternal age, gestational age and parity to 
the nearest date of birth 
3.1. Sample background & social characters:  
3.1.1. Social characters: 
The age of mothers with PIH ranged between 16-45 years. 
The mean age was 27.6 (SD ± 5.6) years. 
The age of controls ranged between 16- 45. The mean age was 
27.6 (SD   ±5.6) years. 
The most attained level of education among mothers of cases 
was secondary school 56(40.0%) and the least common was 
illiterate 7(5.0%). The most attained level of education among 
mothers of controls group was secondary schools 69(49.3%) and 
the least common was university graduated 3(2.1%).  
There were 37 (26.4%) mothers with PIH who had jobs; 
whereas 103 (73.6%) were housewives. Among controls group 
there were 12(8.6%) mothers who had jobs, whereas 128(91.4%) 
were housewife. 
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3.1.2. Parity distribution:  
The cases group contained 75 (53.6%) mothers who were 
primigravida and 65(46.4%) multigravida. The controls group 
included 75 (53.6%) primigravida and 65 (46.4%) multigravida 
mothers. 
3.1.3. Classification of PIH: 
Among mothers having PIH 23 (16.4%) of them diagnosed 
as gestational hypertension, 70 (50.0%) as pre-eclampsia, 26 
(18.6%) had severe pre-eclampsia, 21 (15.0) mothers presented 
with eclamptic fits and no mothers presented with Hellp syndrome.  
Among 65 (46.4%) multigravida, 32 (22.8%) had past history 
of PIH.  21 (65.6%) of them were diagnosed in the first pregnancy, 
5 (15.6%) in the second and 6 (18.8%) were diagnosed in 3rd and 
subsequent pregnancies. 
3.1.4. Mode of delivery and gender of the babies: 
The commonest mode of delivery of cases was caesarian 
section in 101(72.1%) cases and the least mode was breech 
extraction in one case (0.7%). 
           Distribution of gender of newborns of cases were 63 (45.0%) 
males and 77 (55.0%) females.   
3.2. Impact of PIH on growth parameters and maturation: 
3.2.1. Impact of PIH on growth parameters: 
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There was significant difference between head circumference 
centile for infants of cases and controls, with P < 0.0001 as shown 
in Table 1. 
As shown in Tables 2 and 3 we found that there were highly 
significant differences in length centile and weight centile of 
infants of cases compared to control with P < 0.0001 for each. 
Also infants of mothers with PIH have low chest circumference 
compared to control with p < 0.0001 by using Anova. 
The severity of PIH (pre-eclampsia, severe pre-eclampsia and 
eclampsia) proportionately lowered the length and weight of 
newborns cases to a significant effect (P < 0.006 and P< 0.012) 
respectively but did not have significant effect on head 
circumference of newborns cases compared to controls (P=0.077) 
as shown in tables 4, 5 and 6. 
As shown in Tables 7, 8 and 9 PIH starting in early weeks of 
pregnancy had no significant affect on distribution of centile of 
head circumference, length and weight of newborns of cases, with 
P values 0.094, 0.240 and 0.467 respectively. 
Starting of antihypertensive drugs in early weeks of 
pregnancy, showed no significant effect on the distribution of head 
circumference centile, length centile and weight centile as shown 
in Tables 10, 11 and 12, with P values 0.371, 0.258 and 0.822 
respectively.       
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3-2-2 Impact of PIH on maturation: 
Figure1 shows incidence of preterm (<37 weeks) 34(24.8%) 
among cases where as term (≥37weeks) babies were 
106(75.2%).There was no significant difference in distribution of 
preterm babies of cases among primigravida and multigravida 
17(22.6%) versus 17(26.1) P value was 0.663.                                           
Past history of PIH did not significantly affect maturity of 
babies P value 0.193 Figure 2. Table 13 shows no difference in 
distribution of weight centile of preterm and term newborns cases 
with P value 0.149.  
Gestational hypertension and severe pre-eclamsia were 
significant affect maturity with P value <0.01, 0.02 respectively as 
shown in table 14. As shown in Table 15 PIH starting in the early 
weeks of pregnancy was found significantly associated with 
prematurely with P < 0.0001.                                                                       
Starting antihypertensive drugs in early weeks of pregnancy 
significant increase maturation of newborns of mothers having PIH 
as shown in Table 16 with P <0.0001. 
3-3 Impact of PIH on the neonatal morbidity and mortality: 
3-3-1 Neonatal mortality: 
There were five stillbirth newborns among the study group 
and no death in controls groups as shown in Table 17.  
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3-3-2 Resuscitation of newborns: 
             Newborns of study groups who did not cry immediately 
were 29(20.7%) versus 4(2.9%) control with P < 0.0001, OR 
0.11(95%CI 0.04-0.33). It was founds that resuscitation done (in a 
form of tactile stimulation, suction, oxygen and bag & mask 
ventilation) for 59(43.7%) of cases versus 20(14.3%) of controls 
with P < 0.0001, OR 4.6(95%CI2.6-8.3) as shown in Figures 3. 
There were also significant increase in durations of resuscitation 
between cases and control with Fisher’s Exact test <0.002, RR0.66 
(95%0.55-0.79) as shown in Table 18. Apgar scores at 1, 5 and10 
minutes were significantly lower in cases than controls with P < 
0.0001, OR 9.9 (95% CI4.05-24.2) and Fisher’s exact test < 0.0001, 
RR2.1(95%CI 1.88-2.4) and        <0.003,RR2.06(95%CI 1.8-2.3) 
respectively as shown in Tables 19, 20 and 21. Figure 4 shows 
there was no significant difference between newborns of mothers 
having PIH versus control admitted to the nursery, with P value of 
0.751. 
3-3-3 Complications of newborns: 
The significant complications that occurred for newborns of 
cases were hypoglycaemia, perinatal asphyxia and hypothermia 
with Fisher’s exact test< 0.003, <0.015 and <0.0001 respectively. 
RR 2.1 (95%CI 1.85-2.38), OR 5.52 (95%CI 1.19-2.57) and OR 
6.75 (95%CI 2.5-18.1) respectively.  But there were no significant 
 42
difference between cases and controls for apnea, RDS, 
polycythemia and jaundice as shown in Table 22. 
Among newborns  cases there were significant difference in 
preterm to term newborns for apnea 3(10.3%) versus 1(0.9%), 
RDS 4(13.8%) versus non and jaundice 11(37.9%)versus 8(7.5%)  
and Fisher̉׳s Exact Test were 0.039, 0.001 and 0.000 respectively 
whereas no significant difference between preterm and term babies 
of cases for hypoglycaemia, perinatal asphyxia and hypothermia 
with Fisher׳s Exact Test 0.389, 1.000 and P<0.094 respectively. 
Others complications (hypocalcemia, meconium aspiration, 
cephalohaematoma, umbilical sepsis and bacterial conjunctivitis) 
occurs in 12(16.3%) newborns of mothers with PIH, compared to 
3(2.1%) of controls. 
3-3-4 Outcomes of newborns of cases and controls in the first 
six days of life: 
The perinatal outcomes for neonates of cases and controls in 
the first six days of life 107 (76.4%) had no complications and 
recovered without complications compared to 128 (91.4%) 
controls, sill ill in the  nursery and delayed complications 
26(18.6%) versus 11(7.8%) with P < 0.005 OR 2.83 (95%CI 1.33-
5.99) as shown in Table 23. 
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3-4 Knowledge and attitude of mothers of impact of PIH on 
newborns and care of newborns: 
3-4-1 Knowledge of mothers of impact of PIH on newborns and 
pregnancy: 
When mothers of cases and control were asked about 
complications of PIH for neonates, the most common answers 
were increase neonatal loss 80(63.0%) versus 47(37.0%) and the 
least one was decrease neonatal loss and there were three cases 
missing, with P < 0.0001 as shown in Table 24. 
Figure 5 shows knowledge of mothers of  complications of 
PIH in pregnancy with P < 0.0001.When mothers were asked 
about worried there knowing of having PIH, 91(65.0%) of cases 
answers yes versus 67(47.8%) control with P < 0.004.21(23.2%) 
versus 21(31.3%) worried because PIH has impact on themselves, 
24(26.3%) versus 10(15.0%) impact on baby and 46(50.5%) versus 
36(53.7%) because it has impact on both baby and mother with P 
value 0.181. 
There were 125 (89.3%) of mothers with PIH thought that it 
is important for mothers with PIH to deliver in hospital with 
nursery versus 92(65.7%) control P< 0.0001 as shown in Figure 6. 
There was no significant difference of knowledge of 
primigravida and multigravida about impact of PIH on newborns 
with P value 0.176 but there was significant difference between 
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primigravida and multigravida of impact of PIH on pregnancy with 
P < 0.048.There were no significant differences between mothers 
who have past history and those have not on knowledge about 
impact of PIH on newborns(n= 23(71.9%) versus n= 57(54.3%)) 
and complications of PIH for pregnancy(n= 29(90.6%) versus n= 
76(70.4%)) with P values 0.229 and 0.120 respectively. There 
were 91(65.0%) of mothers cases were worried when they know 
having PIH, 21(23%) of them worried because PIH has impact on 
herself, 24(26.4) impact on her baby and 46(50.5) they thought 
PIH has impact on herself and baby with P value 0.780. Was found 
no significant different of worried of primigravida and 
multigravida about PIH 51(68.8%) Vs 40(61.5%) with P value 
0.424. 
Figure 7 and 8 shows mothers having past history of PIH 
were not different from those who had no previous history of PIH 
about worried of impact of PIH. when primigravida and 
multigravida were asked is it essential mothers with PIH to 
delivery at hospital with nursery, 67(89.3%) versus 58(89.2%) they 
thought it is essential with P value 0.984. There were 30(93.8%) 
mothers with past history of PIH they thought it is important to 
deliver at hospital with nursery versus 95(88.0%) had not with P 
value 0.353. There were no significant different about knowledge 
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of mothers having PIH and those who have normal blood pressure 
about importance of nursery for newborns.   
3-4-2 Attitude and practice of mothers toward neonatal care: 
There were 86 (61.4%) of cases versus 105(75.0%) control  
thought that home exposure of neonates to others prone him to 
infection with P < 0.015.There was 5(5.8%) versus 1(0.9%) they 
thought to protect the baby from infection by changing clothes 
regularly with Fisher׳s Exact Test 0.214,  49 (56.9%) versus 
80(76.2%) P < 0.0001 thought isolation. Clean mothers body 
2(2.3%) versus 2(1.9%) with Fisher׳s Exact Test 1.000. Others 
(room ventilation, wash the baby with warm water, clean the 
clothes and feeding) 43(50.0%) versus 44(41.9%) with P value 
0.897 and 16(18.6%) versus 8(7.6%) they did not know how to 
protect the baby from infection with P value 0.088. 
When cases and controls were asked how to keep the baby 
warmth at home, 112(80.0%) versus 98(70.0%) answer by wearing 
heavy clothes P value 0.053. Put beside his mothers 8(5.7%) 
versus 10(7.1%) P value 0.626. Stay at warm place 23(16.4%) 
versus 20(14.3%) with P value 0.619. Avoid exposure to cold 
weather 26(16.4%) versus 18(12.8%) P value 0.189. Others (use 
mosquito net, stop fan and stay at shelter) 24(17.1%) versus 
19(13.6%) P value 0.407 and 6(4.3%) versus 12(8.6%) with P 
value 0.144 they did not know. 
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There were122 (87.1%) of mothers with PIH thought babies 
with low birth weight can catch up her or his appropriate weight, 
4(3.3%) of them thought to reach the baby the ideal weight by 
doing good care, 86(70.5%) of them thought by frequent breast 
feeding, 5(4.1%) by protection from infection and 23(18.8%) of 
mothers by supplementary feeding after four month and only 
4(3.3%) of them they did not know what to do. 
Table25 shows there was no significant difference between 
cases and control for knowledge the best method for follow up 
newborns with P value 0.060. 
About causes of failure to thrive of newborns, 7(5.0%) of mothers 
having PIH versus control 6(4.3%) thought because who had 
already low birth weight, 32 (22.8%) versus69(49.3%) thought due 
to not taking enough food, 63(45.0%) thought due to disease,     
4(2. 8%) as due to inherited diseases , 6(4. 3%) of them thought 
other reason as deficiency of  vitamins and difficulty of digestion 
and 29(20.7%) they did not know the cause.   
Mothers having PIH with jobs were 37, 26 (70.3%) of them 
thought they will stop working to care for her baby, 1(2.7%) 
mentioned they bring him to her work place and 10(27.0%) others 
member from her family to look after him. 
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Table 1: Distribution of head circumference centile of 
newborns of cases (n=140) and controls (n=140)  
 
Head 
circumference 
centile*  
Cases 
n (%) 
Controls 
n (%) 
Total  
n (%) 
              <10 19 (13.6) 3 (2.1) 22 (7.9) 
             10 – 50 85 (60.7) 68 (48.6) 153 (54.6) 
               51 – 90  25 (17.9) 54 (38.6) 79 (28.2) 
                   >90 11 (7.8) 15 (10.7) 26 (9.3) 
Total 140(100.0) 140(100.0) 280(100.0) 
 
  P < 0.0001 
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Table 2: Distribution of length centile of newborns cases(n=140) 
and controls (n=140) 
 
Length centile*  Cases 
n (%) 
Controls 
n (%) 
Total  
n (%) 
                <10 48 (34.3) 10 (7.1)  58 (20.7) 
               10 – 50 71 (50.7) 94 (67.2) 165 (58.9) 
               51 – 90  13 (9.3) 33 (23.6) 46 (16.5) 
                     >90 8 (5.7) 3 (2.1) 11 (3.9) 
Total 140(100.0) 140(100.0) 280(100.0) 
 
  P < 0.0001 
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Table 3: Distribution of weight centile of newborns cases 
(n=140) and controls(n=140) 
 
Weight centile*  Cases 
n (%) 
Controls 
n (%) 
Total 
n (%)  
<10 36 (25.7) 3 (2.1) 39 (13.9) 
10 – 50 77 (55.0) 97 (69.3) 174 (62.2) 
51 – 90 14 (10.0) 30 (21.4) 44 (15.7) 
> 90 13 (9.3) 10 (7. 2) 23 (8.2) 
Total 140(100.0) 140(100.0) 280(100.0) 
 
  P < 0.0001 
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Table 4: Distribution of head circumference centile of the 
newborn cases according to classification of PIH(n=140) 
 
Classification of 
PIH 
Head circumference Centile(C)* Total 
n (%) <10 C 
n (%) 
10-50 C 
n (%) 
51-90 C 
n (%) 
>90 C 
n (%) 
Gestational 
hypertension 
1 (5. 3) 11 (12. 9) 7 (28.0) 4 (36.4) 23(16.4) 
Pre-eclampsia 13 (68.4) 44 (51.8) 7 (28.0) 6 (54. 5) 70(50. 0) 
Severe pre-
eclampsia 
4 (21,0) 16 (18.8) 5 (20.0) 1 (9.1) 26(18. 6) 
Eclampsia 1 (5. 3) 14 (16. 5) 6 (24.0) 0(100.0) 21(15. 0) 
Total 19 (100.0) 85 (100.0) 25(100.0) 11(100.0) 140 (100. 0)
 
  P = 0.077 
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Table 5: Distribution of length centile of newborns cases 
according to classification of PIH (n=140) 
 
Classification 
of PIH 
Length centile( C )  * Total 
n (%) <10 C 
n (%) 
10-50 C 
n (%) 
51-90 C 
n (%) 
>90 C 
n (%) 
Gestational 
hypertension 
 
3 (6. 3) 
 
12 (16. 9) 
 
6 (40.1) 
 
2 (25.0) 
 
23 (16.4) 
Pre-eclampsia 33 (68.7) 29 (40. 9) 4 (30.8) 4 (50.0) 70 (50.0) 
Severe pre-
eclampsia 
 
9 (18.7) 
 
15 (21.1) 
 
2 (15.4) 
 
0(00.0) 
 
26 (18.6) 
Eclampsia 3 (6. 3) 15 (21.1) 1 (7.7) 2 (25.0) 21 (15.0) 
Total 48 
(100.0) 
71 (100.0) 13(100.0) 8 (100.0) 140 (100. 0) 
 
  P < 0.006 
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Table 6: Distribution of weight centile of newborns cases 
according to classification of PIH(n=140) 
 
Classification 
of PIH 
Weight centile( C ) Total 
n (%) <10 C 
n (%) 
10-50 C 
n (%) 
51-90 C
n (%) 
>90 C 
n (%) 
Gestational 
hypertension 
 
0(00.0) 
 
16 (20.8) 
 
3 (21.4) 
 
4 (30.8) 
 
23 (16.4) 
Pre eclampsia 27 (75.0) 34 (44.1) 5 (35.8) 4 (30.8) 70 (50.0) 
Severe pre-
eclampsia 
 
8 (22. 2) 
 
12 (15.6) 
 
3 (21.4) 
 
3 (23.1) 
 
26 (18.6) 
Eclampsia 1 (2.8) 15 (19. 5) 3 (21.4) 2 (15. 3) 21 (15.0) 
Total 36 (100.0) 77 
(100.0) 
14(100.0) 13(100.0) 140 (100. 0) 
  P < 0.012 
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Table 7: Distribution of head circumference centile of newborn 
of cases according to time when PIH was diagnosed (n=140)  
 
Gestational 
when PIH 
was 
diagnosed 
(in weeks) 
Head circumference centile( C ) Total 
n (%) 
<10 C 
n (%) 
10-50 C 
n (%) 
51-90 C
n (%) 
>90 C 
n (%) 
 
<25 0(00.0) 8 (9. 5) 0(00.0) 2 (18.1) 10 (7.1) 
26 – 30 7 (36.8) 11 (12. 9) 4 (16.0) 3 (27. 3) 25 (17. 9) 
31 – 35 8 (42.1) 32 (37.6) 8 (32.0) 3 (27. 3) 51 (36.4) 
≥36 4 (21.1) 34 (40.0) 13 (52.0) 3 (27. 3) 54 (38.6) 
Total 19 (100.0) 85 (100.0) 25(100.0) 11(100.0) 140 (100. 0) 
  P = 0.094 
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Table 8: Distribution of length centile of newborn cases 
according to time when PIH was diagnosed(n=140)  
 
Gestation 
when PIH 
was 
diagnosed 
(in weeks) 
Length centile( C ) Total 
n (%) <10 C 
n (%) 
10-50 C
n (%) 
51-90 C 
n (%) 
>90 C 
n (%) 
<25 2 (4. 2) 5 (7. 0) 3 (23.1) 0(00.0) 10 (7.1) 
26 – 30 11 (22. 9) 9 (12.7) 4 (30.7) 1 (12. 5) 25 (17. 9) 
31 – 35 19 (39.6) 26 (36.6) 3 (23.1) 3 (37. 5) 51 (36.4) 
≥36 16 (33.3) 31 (43.7) 3 (23.1) 4 (50.0) 54 (38.6) 
Total 48 
(100.0) 
71 
(100.0) 
13  
(100.0) 
8 
(100.0) 
140  
(100. 0) 
  P = 0.240 
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Table 9: Distribution of weight centile of newborns cases 
according to time when PIH was diagnosed(n=140)  
 
Gestation 
when PIH 
was 
diagnosed 
(in weeks) 
Weight centile( C ) Total 
n (%) 
<10 C 
n (%) 
10-50 C 
n (%) 
51-90 C 
n (%) 
>90 C 
n (%) 
 
<25 2 (5. 5) 6 (7.8) 0(00.0) 2 (15.4) 10 (7.1) 
26 – 30 9 (25.0) 13 (16. 9) 2 (14.3) 1 (7.7) 25 (17. 9) 
31 – 35 16 (44. 5) 27 (35.1) 5 (35.7) 3 (23.1) 51 (36.4) 
≥36 9(25.0) 31 (40. 2) 7 (50.0) 7 (53.8) 54 (38.6) 
Total 36 (100.0) 77 (100.0) 14(100.0) 13(100.0) 140 (100. 0)
  P = 0.467 
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Table 10: Distribution of head circumference centile of 
newborns cases according to time of start of anti hypertensive 
drugs (n=104)* 
 
Gestation 
when anti 
hypertensive 
was started 
(in weeks) 
Head circumference centile( C ) Total 
n (%) 
<10 C 
n (%) 
10-50 C 
n (%) 
51-90 C 
n (%) 
>90 C 
n (%) 
 
<25 0(00.0) 5 (7.8) 0(00.0) 1 (11.1) 6 (5.7) 
26 – 30 3 (17.7) 10 (15.6) 1 (7.1) 0(00.0) 14 (13. 5) 
31 – 35 6 (35. 2) 24 (37. 5) 4 (28.6) 6 (66.7) 40 (38. 5) 
≥36 8 (47.1) 25 (39.1) 9 (64. 3) 2 (22. 2) 44 (42. 3) 
Total 17 (100.0) 64 (100.0) 14(100.0) 9 (100.0) 104 (100. 0) 
 * Mothers of 36 newborns did not receive antihypertensive drugs.  
 
  P = 0.371 
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Table 11: Distribution of length centile of newborn cases 
according to time when anti hypertensive drugs were started 
(n=104)*  
 
Gestation 
when anti 
hypertensive 
was started 
(in weeks) 
Length centile( C ) Total 
n (%) <10 C 
n (%) 
10-50 C
n (%) 
51-90 
C 
n (%) 
>90 C 
n (%) 
<25 1 (2.6) 3 (6. 0) 2 (22.2) 0(00.0) 6 (5.7) 
26 – 30 5 (12.8) 8 (16.0) 0(00.0) 1 (16.7) 14 (13. 5) 
31 – 35 15 (38. 5) 17 (34.0) 6 (66.7) 2 (33. 3) 40 (38. 5) 
≥36 18 (46.1) 22 (44.0) 1 (11.1) 3 (50.0) 44 (42. 3) 
Total 39 
(100.0) 
50 
(100.0) 
9 
(100.0) 
6 
(100.0) 
104  
(100.0) 
 *Mothers of 36 mewborns did not receive antihypertensive drugs.   
 
P = 0.258 
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Table 12: Distribution of weight centile of newborn cases 
according to time when anti hypertensive drugs were started 
(n=104)*  
 
Gestation 
when anti 
hypertensive 
was started 
(in weeks) 
Weight centile( C ) Total 
n (%) 
<10 C 
n (%) 
10-50 C
n (%) 
51-90 
C 
n (%) 
>90 C 
n (%) 
 
<25 1 (3. 5) 4 (6. 9) 0(00.0) 1 (12. 5) 6 (5.7) 
26 – 30 6 (20.7) 7 (12.1) 1 (11.1) 0(00.0) 14 (13. 5) 
31 – 35 11 (37. 9) 21 (36. 2) 5 (55.6) 3 (37. 5) 40 (38. 5) 
≥36 11 (37.9) 26 (44.8) 3 (33.3) 4 (50.0) 44 (42. 3) 
Total 29  
(100.0) 
58 
(100.0) 
9 
(100.0) 
8 
(100.0) 
104 
 (100.0) 
 * Mothers of 36 newborns did not receive antihypertensive drugs.   
 
P = 0.822 
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Table 13: Distribution of weight centile for preterm and term 
newborns of mothers with PIH (n=140) 
 
Weight centile Gestational 
age(weeks) 
Total 
n (%) 
< 37 
n (%) 
≥ 37 
n (%) 
<10 13 (38.2) 23 (21.7)  
10 – 50 16 (47.1) 61 (57.6)  
51 – 90 4 (11.8) 10 (9.4)  
>90 1 (2. 9) 12 (11.3)  
Total 34 (100.0) 106 (100.0) 140 (100.0) 
 
P = 0.149 
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Table 14: Distribution of preterm and term newborn cases 
according to classification of PIH (n=140) 
 
Classification of 
PIH 
Gestational 
age( inweeks) 
Total 
 
P value 
< 37 
n (%) 
≥ 37 
n (%) 
n (%)  
Gestational 
hypertension 
 
2 (5. 9) 
 
21 (19.9) 
 
23 (16.4) 
 
 0.01 
Pre-eclampsia 15 (44.1) 55 (51.9) 70 (50.0)  0.5 
Sevre pre-eclampsia 11 (32.4) 15 (14.1) 26 (18.6)  0.02 
Eclampsia 6 (17.6) 15 (14.1) 21 (15.0)  0.05 
Total 34 (100.0) 106 (100.0) 140 (100.0)  
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Table 15: Distribution of preterm and term newborn cases 
according to time of diagnosis of PIH (n=140) 
 
Gestation when 
PIH was diagnosed 
Preterm Term Total 
n (%) < 37 
n (%) 
≥ 37 
n (%) 
< 25 4 (11.8) 6 (5.7) 10 (7.1) 
26 – 30 11 (32.3) 14 (13.2) 25 (17.9) 
31 – 35 17 (50.0) 34 (32.1) 51 (36.4) 
≥ 36 2 (5. 9) 52 (49.0) 54 (38.6) 
Total 34 (100.0) 106 (100.0) 140 (100.0) 
 
P < 0.0001 
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Table 16: Relation between preterm and term newborn cases 
and time of start of anti hypertensive drugs (n=104)* 
 
Gestation when 
anti hypertensive 
was started (weeks) 
Gestation age(weeks) Total 
n (%) < 37 
n (%) 
≥ 37 
n (%) 
< 25 3 (9.7) 3 (4.1) 6 (5.7) 
26 – 30 9 (29.0) 5 (6. 8) 14 (13.5) 
31 – 35 16 (51.6) 24 (32.9) 40 (38.5) 
≥ 36 3 (9.7) 41 (56.2) 44 (42.3) 
Total 31 (100.0) 73 (100.0) 104 (100.0) 
* Mothers of 36 newborns did not receive antihypertensive drugs.   
P < 0.0001 
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Table 17: Outcome of delivery for cases (n=140) and controls 
(n=140) 
 
Outcome of 
delivery 
Cases 
n (%) 
Controls 
n (%) 
Total 
n (%) 
Alive 135 (96.4) 140 (100.0) 275 (98.7) 
Stillbirth 5(3.6) 0 (00.0) 5 (1.3) 
Total 140(100.0) 140(100.0) 280(100.0) 
P = 0.06 
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Table 18: Duration of resuscitation received (in minutes) for 
cases (n=59)● and controls (n=20)* 
 
Duration of 
resuscitation 
received (in min) 
Cases 
n (%) 
Controls 
n (%) 
Total 
n (%) 
≤ 2 39 (66.1) 20 (100.0) 59 (74.7) 
≥ 3 2o (33.9) 0(00.0) 20 (25.3) 
Total 59 (100.0) 20 (100.0) 79 (100.0) 
* 120 newborns of mothers of control did not receive resuscitation. 
●81 newborns of mothers of cases did not receive resuscitation. 
P < 0.002 
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Table 19: Apgar score at one minute for cases (n=140) and 
controls (n=140) 
 
Apgar score one 
minute 
Cases 
n (%) 
Controls 
n (%) 
Total 
n (%) 
≤ 7 43 (30.7) 6 (4.3) 49 (17.5) 
≥ 8 97 (69.3) 134 (95.7) 231 (82.5) 
Total 140(100.0) 140(100.0) 280 (100.0) 
  P < 0.0001 
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Table 20: Apgar score at 5 minute for cases (n=140) and 
controls (n=140) 
 
Apgar score  5       
minutes  
Cases 
n (%) 
Controls 
n (%) 
Total 
n (%) 
≤ 7 17 (12.1) 0(00.0) 17 (6.1) 
≥ 8 123 (87.9) 140 (100.0) 263 (93.9) 
Total 140(100.0) 140(100.0) 280 (100.0) 
P < 0.0001 
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Table 21: Apgar score at 10 minute for cases (n=140) and 
controls (n=140) 
 
Apgar score 10 
minute 
Cases 
n (%) 
Controls 
n (%) 
Total 
n (%) 
≤ 7 9(6.4) 0(00.0) 9 (3.2) 
≥8 131 (93.6) 140 (100.0) 271 (96.8) 
Total 140(100.0) 140(100.0) 280(100.0) 
Fisher’s exact test < 0.003 
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Table 22: Neonatal complications for newborns of cases (n=73) 
and controls (n=24) 
 
Neonatal 
complications 
Cases 
n (%) 
Controls
n (%) 
Total 
n (%) 
P 
value 
 OR (95%CI)
Apnea 4(5.5) 0(00.0) 4 (4.1) 0.057*  
Hypoglycaemia 8 (10.9) 0(00.0) 8 (8.2) 0.003  
Perinatal 
asphyxia 
10 (13.7) 2(8.3) 12 (12.4) 0.015 5.52(1.18-25.7) 
Hypothermia 27 (37.0) 5 (20.8) 32 (33.0) 0.000 6.75(2.51-18.1) 
RDS 4(5.5) 1(4.2) 5 (5.2) 0.207* 4.2 (0.47-38.5) 
Polycythemia 1(1.4) 0(00.0) 1(1.0) 0.491*  
Jaundice 19 (26.0) 16 (66.7) 35 (36.1) 0.510  
Total 73(100.0) 24(100.0) 97(100.0)   
OR = Odds Ratio 
CI = Confidence Interval  
* = Fisher‘s exact test  
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Table 23: Perinatal outcome for cases (n=133)* and controls 
(n=139)• 
 
Outcome (in 6 days) Cases 
n (%) 
Controls 
n (%) 
Total 
n (%) 
Still ill in the nursery &        
Delayed complications 
 
26(18.6) 
 
11(7.8) 
 
37(13.2) 
No complications & 
Recovered                              
without   complications 
 
 
107(76.4) 
 
 
128(91.4) 
 
 
235(83.9) 
 
Total 
 
133(95.0) 
 
139(99.2) 
 
272(97.1) 
  P < 0.005                                
* 5 cases are stillborn and 2 neoborn were lost for follow up. 
 
• one case lost for follow up 
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Table 24: Knowledge of mothers of cases (n=137)* and controls 
(n=140) for complications of PIH in neonates  
 
Complications of 
PIH for neonates 
Cases 
n (%) 
Controls 
n (%) 
Total 
n (%) 
Increased neonatal 
loss 
 
80 (57.1) 
 
47 (33.6) 
 
127 (45. 3) 
Has no effect 17 (12.1) 30 (21.4) 47 (16.8) 
Decrease neonatal 
loss & she does not 
know 
 
40 (28.6) 
 
63 (45.0) 
 
103 (36.8) 
Total 137 (97.8) 140 (100.0) 277 (98. 9) 
                                            Missing 3 
P <0.0001 
* Missing 3 cases  
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Table 25: Knowledge of mothers of cases and controls for the 
best method for follow up newborns weights  
 
Best method for follow 
up newborns 
Cases 
n (%) 
Controls 
n (%) 
Total 
n (%) 
Weight monthly 110 (78.6) 103 (73.6) 213 (76.1) 
Follow up with growth 
chart 
20 (14.3) 33 (23.6) 53 (18.9) 
By mother assessment 6 (4. 3) 3 (2.1) 9 (3. 2) 
She doesn’t know 4 (2.8) 1 (0.7) 5 (1. 8) 
Total 140(100.0) 140(100.0) 280(100.0) 
 
P = 0.060 
 
 
 
 
 
 
 
 
 
 
 72
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 73
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 74
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 75
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 76
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 77
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 78
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 79
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 80
4- DISCUSSION 
4.1. Impact of PIH on growth parameters:  
This study was done in mothers who received antenatal care 
in teaching hospitals with well- training staff and good facilities so 
the results represent a selected group of mothers.  
In our study PIH significantly lowered the birth weight as 
found in literature (48,49,51,61) and also significantly lowered head 
circumference, length and chest circumference. This can be 
explained by pathology that occurs in the placenta.  Trophoblast 
invasion remains superficial and the spiral arteries remain 
muscular which lead to reduced uteroplacentar blood flow (1). 
PIH starting early weeks of pregnancy had no significant 
effect on head circumference, length and weight of newborns of 
cases but severe PIH had significant impact on length weight but 
not on head cicumference this indicat the more increase in blood 
presure had amjor impact on arteriol of the uterus than the mild 
blood presure start early. 
Severe PIH had impact on weight and length and not on head 
circumference because fetus with mother having PIH terminate 
rapidly, so the effect of high blood had short duration on the 
pathology of uterus blood circuration. Head circumference reatch 
large size early than increase in length and weight in the fetus, so 
the impact occur on length and weight than head circumference. 
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Start of antihypertensive drugs early had no effect on growth 
parameters, this can be explained that antihypertensive drugs lower 
blood pressure of the mother but not change the pathology occurs 
on uterus circulation.   
4.2. Impact of PIH on maturation of newborns: 
The rate of preterm newborns among study group were found 
to be 24.8%, This is less than the results reported by Buya & lumu 
who found the incidence of 34%. This difference can be explained 
that study of Buya includes large sample size (72). Past history of 
PIH did not significantly increase premature birth (P= 0.193), this 
is not consistent with study done by Sibai, which showed that 
women who had recurrent pre-eclampsia and severe pre-eclampsia 
had significantly increased prematurity (54). 
      Gestation hypertension and severe pre-eclampsia were 
significantly affect maturation of the newborns P value 0.01, 0.02 
respectively this is not consistent with study done by Davidge in 
China that reported the risk of preterm birth was not increased with 
any classification of PIH (62). 
No difference between primigravida and multigravida having PIH 
to born preterm, because the effect of increase in blood presure in 
the uterus the same in two groups. 
Starting of antihypertensive drugs in early weeks of pregnancy 
significantly increase maturation of newborns, this can be 
 82
explained that antihypertensive drugs drop the blood pressure to 
normal range and obstetrician avoid to terminate the pregnancy. 
4.3. Neonatal morbidity and mortality: 
In our study perinatal mortality was 43/1000 birth. The 
percentage of stillbirth 5(3.5%), this is less than in study done by 
Galanti B, which was 14 %( 60). Among eclamptic cases (21 cases) 
there were one fresh stillbirth and one newborn died after three 
days due to complication of meconium aspiration giving perinatal 
mortality of 9.5%. This is less than mortality found in studies in 
Essnki, Dongolla and Omdurman hospitals. This can be explained 
by the good care in our study area (43,44,45). 
There was significant increase in duration of resuscitation 
(Fisher’s exact test < 0.002) and was similar to study done by Beke 
and Rigo that they found pre-eclampsia increase time of ventilation 
(68). 
In our study Apgar scores at one and 5 minutes were 
significantly lower in cases than controls. This is consistent with 
studies done by Galanti and his collages in Buenos Aires hospital 
in Italia. (60) 
There were 26 newborns referred to nursery in our study. 
This is higher than a study done in the obstetric division of the 
university Messina, in which five newborns were referd to nursery 
among study group of 123 newborns with mother having PIH. This 
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increase in number can be explained by high complications in the 
study groups due to poor facility in our theaters and labour rooms 
compared to that study. (64) 
Hypoglycaemia occurred two times more in newborns of 
mothers with PIH than in controls. There were five times more 
chances to develop perinatal asphyxia and about seven times more 
to develop hypothermia in newborns with mothers with PIH than 
newborns controls. There were also three times greater risks to stay 
ill in the nursery and to develop delayed complications in 
newborns with mothers with PIH compared to newborns controls 
during the first six days of life.  Hypoglycaemia and hypothermia 
can be explained by the most cases were SGA and premature who 
were more susceptible to these complications. However, RDS is 
not found to significantly complicate the newborns cases in this 
study (P= 0.207). This is not consistent with what is reported in the 
literature (56,58,65). 
4.4. Knowledge of mothers of impact of PIH on newborns: 
There were about 60 (37%) mothers who did not know 
complications of PIH for neonates and 25% did not know 
complications of PIH on pregnancy. This indicates that during 
antenatal follow-up, there was not enough teaching about 
complications of PIH and fatal disease which was common.     
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Over one third of mothers (n= 49 (35.0%)) were not worried 
when they know they have PIH. This can be explained by deficient 
health education. These women may not be well adherent to 
follow-up in future pregnancy and may end up with complication 
in newborns. 
There were no significant difference between multigravida 
and primigravida for knowledge of impact of PIH on newborns. 
This indicated that previous pregnancies did not increase their 
knowledge; even those who had experienced PIH in their previous 
pregnancies were not significantly different from those who had 
PIH for the first time. 
There were 59.4% mothers with past history of PIH who 
were worried about PIH in current pregnancy compared to 66.7% 
of mothers with first time of PIH. This result also confirms that no 
adequate health education about PIH is delivered. 
4.5. Knowledge and attitude of mothers toward neonatal 
feeding and care:  
         When mothers having PIH asked how to protect the baby 
from infection, all of them did not mention that vaccination 
protects babies and only 56.9% thought isolation. Small numbers 
mentioned washing newborn with warm water. This indicates 
mothers did not know the good practice toward newborns care. 
Mothers having PIH like controls were knowledgeable about how 
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to keep newborns warm at home and that the best method for 
follow-up baby weight. 
         Most mothers having PIH know that babies can catch up his 
or her appropriate weight and how to care fore gaining weight, this 
indicate proper health education about care of newborns. 
There were 51 (36.4%) of mothers having PIH who did not 
know the reasons that cause failure of the baby to gain weight. 
This is also consistent with deficient health education of mothers 
about newborns feeding. 
About three quarter of mothers having PIH, think to stop 
their works to look after their baby. This thinking may decline their 
income and lead to more adverse effect of their baby health.      
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CONCLUSIONS AND RECOMMENDATIONS 
 
Conclusions: 
• PIH in mothers significantly lowered growth parameters of 
newborns (head circumference, length, weight and chest 
circumference). 
• Maternal PIH increased the incidence of preterm newborns 
(240/1000). 
• PIH starting in early weeks of pregnancy did not significantly 
affect head circumference, length or weight of newborns but 
had significant association with prematurity.  
• Control of PIH in early weeks of pregnancy did not 
significantly improve head circumference, length and weight, 
but increased maturation of newborns. 
• Stillbirth rate was found to be high (36/1000) among mothers 
with PIH. 
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• PIH significantly lowered Apgar scores of newborns at one , 5 
and 10 minutes and significantly increased the duration of 
resuscitation of newborns. 
•  Hypoglycaemia, perinatal asphyxia and hypothermia were 
significantly increased in newborns of mothers with PIH but 
there were no significant difference in occurrence of apnea, 
RDS, polycythermia or jaundice between cases and controls. 
• Mothers having PIH were more knowledgeable about impact 
of PIH on newborns and pregnancy than controls and were 
more worried about their outcome. 
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Recommendations:   
• Labuor room and theater in Soba University Hospital and 
Khartoum Teaching Hospital should be supplemented with 
neonatal resussitair and heat radiators. Because most 
pregnant mothers having PIH are referred to this hospitals.  
• The number of incubators in both hospitals should be 
increased since they are referral hospitals. 
• The space of nursery in Khartoum Teaching Hospital should 
be increased and staff and equipments should be upgraded, so 
as to improve treatment complications occuring in newborns 
of mothers having PIH.  
•  Paramedical staff should be directed to encourage mothers 
having PIH for early breast-feeding to avoid hypoglycaemia.  
• All primigravida should receive teaching during antenatal 
follow up about PIH and its complications as well as care of 
newborns.      
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IMPACT OF PREGNANCY INDUCED HYPERTENSION  
ON NEWBORNS IN KHARTOUM STATE 
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Serial No: 
 
Date :                                                                         Tel. No.: 
(A) History of mother: 
1) Name:……………………… (2) Residence: ………….3) Tribe…………………. 
(4) Job: ……………………………. 
(5) Age in years:                        
(6) 1.  Gravida: 
2. Para: 
3. No. Of stillbirths. 
4. No. Of abortions.   
(7) Education in years (0=illiterate):            
(8) Past history of PIH: 
 (1) Yes                      (2) No 
(9) If yes at which pregnancy PIH was first diagnosed:  
(10) Symptoms: 
(1) Headache                (2) Visual changes            (3) Convulsion  
(4) Nausea                    (5) Vomiting                       (6) Abdominal pain 
(7) Dysuria                    (8) Oliguria                          (9) No symptoms 
(11) Signs: 
(1) High blood pressure                       (2) L.L oedema               
 (3) Sudden weight gains                       (4) Retinal change                                          
(12) BP at time of delivery: 
1. Systolic                                         2.  Diastolic 
(13) Investigations: 0 = No      1 = Yes 
(1) Proteinuria                            (2) Abnormal liver function 
(3) Abnormal kidney function                 (4) Low platelets  
(5) High serum uric acid                  
  2 
(14) Diagnosis: 
(1) PIH.      (2) Pre-eclampsia.  (3) Eclampsia.        
(4) Severe pre-eclampsia                  (5) Hellp syndrome.  
(15) Gestation when PIH was diagnosed (in weeks): 
(16) Put on treatment:   (1) Yes              (2) No 
(17) Gestation when antihypertensive was started (in weeks):  
(18)Antihypertensive drug used: 1). …………..2)…..…...………3)………..…..… 
(19) Gestational age:  
1. By date (In weeks). 
2. By fundal assessment (In weeks).    
3. By U/S (In weeks). 
(2o) Mode of delivery: 
(1) Normal vaginal delivery.     (2) Induced       (3) C/S. 
(4) Augmented vaginal delivery.      (5) Forceps.       (6) Ventose. 
(7) Breech extraction.  
 (B) Newborn: 
(21)- Estimation of gestational age according to Ballard scores: (In weeks)  
(22)- Outcome of delivery:     (1) Alive.                (2) Macerated stillbirth. 
(3) Fresh stillbirth. 
(23)- Sex:                                        (1) Male.                  (2) Female 
(24)- Cry immediately:               (1) Yes                      (2) No 
(25)- Apgar score     1m     in              5min                         10  min    
(26)- Neonatal complication:   
1. Apnea:                                                 (1) Yes         (2) No 
2. RDS:            (1) Yes         (2) No 
3. Hypoglycemia:      (1) Yes         (2) No 
4. Polycythemia:      (1) Yes         (2) No 
5. Perinatal asphyxia:              (1) Yes         (2) No 
6. Jaundice:                                           (1) Yes         (2) No 
7. Hypothermia:                                  (1) Yes         (2) No 
8. Others: (Specify) …………………………………………………………… 
……………………………………………………………………………………. 
(27)- Resuscitation done:     (1) Yes        (2) No 
(28)- Duration of resuscitation received (In minutes):  
  3 
(29)- Resuscitation received:  (1) Tactile stimulation              (2) Suction         
                                                      (3) O2                                          (4) Ventilation. 
(30)- Outcome of Resuscitation:         (1) Alive              (2) Death 
(31)- if alive:    
(1) Referred to nursery.                 (2) Put beside his/her mother 
(32)- Anthropometrics measurement: 
(1) Head circumference  ……………cm  (percentile)…… 
(2) Length …………………………… cm (percentile) ….... 
(3) Weight  …………………………… kg (percentile) ….... 
(4) Chest circumference ……………..cm (percentile)…….. 
(33)- Outcome (In 6 days): 
1. No complications. 
2. Still ill in nursery. 
3. Lost for follow up. 
4. Recovered without complications. 
5. Recovered with complications.  
6. Delayed complications. 
7. Died. 
                      ( C)   KAP  Study  
(34) Has PIH impact on newborn: 
 (1) Yes                        (2) No               (3) She does not know 
(35) Complication of PIH for neonate: 
 (1) Increase neonatal loss               (2) Decrease neonatal loss 
 (3) Has no effect                              (4) She does not know 
(36) Complication of PIH for the pregnancy: 
 (1) Increase duration of pregnancy                  (2) Decrease duration  
 (3) No effect                                                         (4) She does not know                                       
(37) Are you worried when known you have PIH: 
 (1) Yes            (2) No 
(38) If yes why you are worried because the PIH has impact: 
(1) On your self. 
(2) On your baby. 
(3) On your self and your baby. 
(4)  Others (Specify) ………………………………………………… 
  4 
(39) Is it essential mother with PIH to delivery at hospital with nursery? 
 (1) Yes                       (2) No 
(40) If yes why it is essential: 
(1) ………………………………………………. 
(2) ………………………………………………. 
(3) ………………………………………………. 
(41) At home exposure of the neonate to others prone him to infection: 
 (1) Yes                    (2) No 
(42) How to protect the baby from infection? 
…………………………………………………………………………………………
…………………………………………………………………………………………
………………………………………………………………………………………… 
(43) How to keep the baby warm at home: 
a. ………………………………………………………………… 
b. ………………………………………………………………… 
c. ………………………………………………………………… 
(44) Which is better for your baby? 
 (1) Breast milk                   (2) Formula milk         (3) Cow's milk 
(45) Why breast milk is better? 
 (1) Protect the baby from infection 
 (2) Increase mother baby bonding  
 (3) Less cost                                           
(4) All of the above 
(5) She does not know  
(46) If the answer formula milk why? 
…………………………………………………………………………………………
………………………………………………………………………………………....  
(47) Which is better for the baby to gain normal growth? 
 (1) Breast feed on demand.                       
            (2) Breast feed & bottle-feeds. 
 (3) Breast feeding with starting early supplementary feeding.  
 (4) Breast feeding with starting supplementary feeding at 4 month of age. 
 (5) She does not know. 
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(48) If your baby has low birth weight can he or she catch up to normal 
weight? 
 (1) Yes           (2) No     (3) she does not know 
(49) What to do for your baby to catch up the normal weight? 
i- ……………………………………………………………………………. 
ii- ……………………………………………………………………………. 
iii- ……………………………………………………………………………. 
(50) The best method for follow up baby weight gain is: 
(1) Weighing monthly. 
(2) Weighing regularly & follow up with growth chart.  
(3)  By your assessment. 
(4)  She does not know.  
(51) If your baby fails to gain weight, this may be due to: 
i- ……………………………………………………………………………… 
ii- ……………………………………………………………………………… 
iii- ……………………………………………………………………………… 
(52) If mother has job, she wishes to care for her baby by: 
(1) Stop working. 
(2) Bring the baby to her work place (nursery). 
(3) Other members from her family to look after for him. 
(4) Bring him or her to nursery. 
(5) Others (Specify) ………………………………………………………… 
…………………………………………………………………………………  
  
 
 
